PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).
Renske Kornalijnslijper-Altena(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Thomas Hatschek(Karolinska University Hospital), Yvonne Brandberg(Karolinska Institutet), Fredrika Killander(Lund University), Barbro Linderholm(Karolinska University Hospital), Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Antonios Valachis(Örebro University Hospital), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Hanjing Xie(Saint Göran Hospital), Luisa Edman Kessler(Karolinska Institutet), Johan Hartman(Karolinska University Hospital), Anna Karin Wennstig(Sundsvall Municipality), Ellinor Elinder(Stockholm South General Hospital)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k